Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical NK Cells for AML Remission Consolidation
NCT06783478Phase 2Not yet recruiting
- Sponsor
- Hospital de Clínicas de Porto Alegre
- Start
- Apr 2025
- Primary completion
- Aug 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of haploidentical natural killer cells in acute myeloid leukemia (AML), sponsored by Hospital de Clínicas de Porto Alegre. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
haploidentical natural killer cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06783478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06783478.